Company Statement: Sanofi and Glenmark Pharmaceuticals sign license agreement on monoclonal antibody for crohn's disease and other chronic autoimmune disorders
MLex Summary: Sanofi has announced that its has entered into a licensing agreement with Glenmark Pharmaceuticals to facilitate the development of GBR500, a new monoclonal antibody to treat crohn's disease and other similar...To view the full article, register now.
Already a subscriber? Click here to view full article